Rheumatoid disease is a chronic autoimmune condition in which the immune system mistakenly attacks the body’s own tissues, most notably the joints but also organs like the heart, lungs, eyes, and skin. While most people know it as “rheumatoid arthritis” or RA, the term “rheumatoid disease” reflects something important: this is not just an arthritis problem. It is a systemic illness that affects the entire body. As of 2019, roughly 18 million people worldwide were living with it, and women account for about 70% of cases.
More Than Joint Pain
The hallmark of rheumatoid disease is inflammation in the lining of the joints, called the synovium. In a healthy joint, this lining is thin and free of immune cells. In rheumatoid disease, immune cells flood the synovium and release inflammatory molecules that cause swelling, pain, and stiffness. Over time, this process erodes cartilage and bone, leading to permanent joint damage if left untreated.
But the inflammatory molecules produced in the joints don’t stay there. They circulate throughout the body and can damage tissue far from any joint. This is why calling it a “disease” rather than just “arthritis” matters. The joints are often where symptoms start, but they’re not where the condition ends.
What It Feels Like
The earliest and most distinctive symptom is morning stiffness that lasts at least 30 minutes, and often longer than an hour. This isn’t the brief creakiness most people feel when they first get out of bed. It’s a deep, persistent stiffness that gradually loosens over the course of the morning. The affected joints are typically warm, swollen, and tender to the touch.
Rheumatoid disease tends to be symmetrical, meaning it affects the same joints on both sides of the body. If your left wrist is inflamed, your right wrist likely is too. It favors the small joints first, particularly the fingers, wrists, and toes, though it can involve any joint. Fatigue is another common early symptom, sometimes so pronounced that it’s the thing that drives people to seek medical attention before joint pain becomes obvious.
What Happens Inside the Body
The immune system normally uses inflammation to fight infections. In rheumatoid disease, that same process fires without a real threat. Specific immune cells, including T cells, B cells, and natural killer cells, become activated and begin producing inflammatory signaling molecules. Two of the most damaging are tumor necrosis factor (TNF-alpha) and interleukin-6 (IL-6).
TNF-alpha does several harmful things at once. It increases the number of bone-destroying cells (osteoclasts), promotes their maturation, and drives enzymes that break down cartilage. IL-6 works alongside it to stimulate osteoclast development, accelerating bone erosion. This is why untreated rheumatoid disease doesn’t just cause pain. It physically dismantles the joint’s structure over months and years.
Effects Beyond the Joints
The systemic nature of rheumatoid disease means it can show up in places you might not expect. Firm lumps called rheumatoid nodules can form around pressure points like the elbows, and sometimes inside the lungs or heart. Many people develop secondary Sjögren’s syndrome, a condition that significantly reduces moisture in the eyes and mouth, leading to chronic dryness. The lungs, heart, blood vessels, nerves, and skin can all be affected.
The cardiovascular effects are particularly serious. People with rheumatoid disease face roughly double the risk of heart attack compared to the general population. The risk of stroke is about 50% higher. The risk of congestive heart failure is nearly doubled, and venous blood clots are more than twice as likely. These risks stem from the same chronic, body-wide inflammation that damages the joints. Controlling the disease’s inflammatory activity is one of the most effective ways to protect the heart.
How It’s Diagnosed
There is no single test that confirms rheumatoid disease. Diagnosis relies on a combination of physical findings, blood tests, and symptom duration, scored on a point system developed by the American College of Rheumatology and the European League Against Rheumatism. A score of 6 out of 10 qualifies as definite RA. Points come from four categories: how many and which joints are involved, blood markers, signs of inflammation, and whether symptoms have lasted six weeks or more.
The two key blood markers are rheumatoid factor (RF) and anti-CCP antibodies. Anti-CCP is the more precise test. It correctly identifies about 65% of people who have the disease (its sensitivity), but when it comes back positive, it’s right roughly 96% of the time (its positive predictive value). Rheumatoid factor picks up more cases, with sensitivity ranging from 55% to 90%, but it also comes back positive in people who don’t have RA, giving it a positive predictive value of only about 30%. A high-positive result on either test carries more diagnostic weight than a low-positive one.
Some people test negative on both markers and still have rheumatoid disease. This is called seronegative RA. A person who scores below 6 on the classification system at their first evaluation may still meet the criteria later as the disease progresses.
How It’s Treated
The goal of treatment is to suppress the immune system’s attack enough to prevent joint damage and reduce body-wide inflammation. This is done with a class of medications called disease-modifying antirheumatic drugs, or DMARDs. The most commonly used traditional DMARD is methotrexate, which has been a cornerstone of treatment for decades. It’s typically the first medication prescribed after diagnosis.
If traditional DMARDs don’t control the disease adequately, biologic DMARDs are the next step. These are engineered proteins that target specific parts of the immune response. Some block TNF-alpha, directly counteracting one of the main drivers of joint and bone destruction. Others target different immune pathways. A newer class, called JAK inhibitors, works by interrupting the signaling inside immune cells that tells them to produce inflammatory molecules. These are taken as pills rather than injections, which some people prefer.
The current treatment philosophy is called “treat to target,” meaning medications are adjusted until a specific goal is reached, usually low disease activity or remission. Early, aggressive treatment produces the best long-term outcomes. People diagnosed and treated within the first few months of symptoms have a significantly better chance of avoiding permanent joint damage than those who wait.
Who Gets It and Why
Women are two to three times more likely to develop rheumatoid disease than men, and the condition most commonly appears between ages 30 and 60, though it can start at any age. The exact cause remains unknown, but it involves a combination of genetic susceptibility and environmental triggers. Smoking is the strongest known environmental risk factor. Hormonal differences likely explain part of the gender gap, as disease onset and flares sometimes correlate with hormonal shifts like pregnancy and menopause.
Having a first-degree relative with RA increases your risk, but most people who carry the associated genes never develop the disease. Something in the environment, whether an infection, tobacco exposure, or another trigger, appears to flip the switch in genetically predisposed individuals.